Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are intended to provide the clinician with an overview of this medication class. Its purpose is to introduce the clinician to major mechanisms of action, chemical structure, clinical effect, and select precautions/contraindications of NSAIDs.
Keywords
- Nonsteroidal anti-inflammatory drugs
- NSAIDs
- Nonselective COX inhibitors
- Selective COX inhibitors
- NSAID-induced adverse effects
- Aspirin-induced asthma
- Analgesic nephropathy
- NSAID mechanism of action
- NSAID side effects
- NSAID adverse reactions
- NSAID precautions
- NSAID contraindications
- COX-2 inhibitors
- Aspirin
- Acetaminophen
- Celecoxib
- Valdecoxib
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- CNS:
-
Central nervous system
- COX:
-
Cyclooxygenase
- FDA:
-
Federal Drug Administration
- NSAID:
-
Nonsteroidal anti-inflammatory drug
- PDR:
-
Physician’s desk reference
- PGE2 :
-
Protglandin E2
- PGI2 :
-
Prostaglandin I2
- TXA2 :
-
Thromboxane A2
References
Parr G, Darekar B, Fletcher A, Bulpitt CJ. Joint pain and quality of life; results of a randomised trial. Br J Clin Pharmacol. 1989;27(2):235–42.
Katz J. NSAIDs and COX-2-selective inhibitors. In: Benzon H, Raja S, Molloy R, Liu S, Fishman S, editors. Essentials of pain medicine and regional anesthesia. 2nd ed. Philadelphia: Elsevier; 2005. p. 141–58.
Abramson S. Therapy with and mechanisms of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol. 1991;3(3):336–40.
Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol. 1997;400A:167–70.
Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol. 1995;355(2):296–315.
Burke A, Smyth EM, FitzGerald GA. Analgesic-antipyretic agents; pharmacotherapy of gout. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. Columbus: McGrawHill; 2006. p. 671–716.
Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325(7365):619.
Fry SW, Seeff LB. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North Am. 1995;24(4):875–905.
Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. 1987;32(1):1–12.
Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110(3):419.
Leese PT, Talwalker S, Kent JD, Recker DP. Valdecoxib does not impair platelet function. Am J Emerg Med. 2002;20(4):275–81.
Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40(2):124–32.
García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109(24):3000–6.
FDA website. Information for healthcare professionals: non selective non steroidal antiinflammatory drugs (NSAIDs). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085282.htm. Page last updated 27 Jan 2010. Accessed 14 Jan 2013.
Szczeklik A, Nizankowska E, Mastalerz L, Szabo Z. Analgesics and asthma. Am J Ther. 2002;9(3):233–43.
Ivi SS, Krishna MT, Sampson AP, Holgate ST, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest. 2001;119(5):1533–46.
Gerstenfeld LC, Thiede M, Seibert K, Mielke C, Phippard D, Svagr B, Cullinane D, Einhorn TA. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res. 2003;21(4):670–5.
Maxy RJ, Glassman SD. The effect of nonsteroidal anti-inflammatory drugs on osteogenesis and spinal fusion. Reg Anesth Pain Med. 2001;26(2):156–8.
Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 1995;35(3):209–19.
Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153(14):1665–70.
Buvanendran A, Lipman AG. Nonsteroidal anti-inflammatory drugs and acetaminophen. In: Fishman SM, Ballantyne JC, Rathmell JP, editors. Bonica’s management of pain. 4th ed. Baltimore: Lippincott Williams & Wilkins; 2010. p. 67190–965.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Chandran, S. (2015). Nonsteroidal Anti-inflammatory Drugs (NSAIDs). In: Sackheim, K. (eds) Pain Management and Palliative Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2462-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2462-2_10
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2461-5
Online ISBN: 978-1-4939-2462-2
eBook Packages: MedicineMedicine (R0)